Payment overview · 2025
General Payments
$763.73
8 reported records · 7 companies
Healthcare provider profile · identity verified
Alexander D Millis, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine|Endocrinology, Diabetes & Metabolism · MIDLOTHIAN, VA · NPI 1427319011
Verified facts
What the public records show
CMS Open Payments records show Alexander D Millis, M.D. received $763.73 in general payments during 2025 across 8 reported records.
Sequel Med Tech, LLC accounted for 19.6% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 6 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Jardiance.
Amgen Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PROLIA as an associated drug or biological on 20867 records involving 11744 distinct recipient NPIs. Public Medicare Part D data also shows 34 claims for Prolia by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 229 claims for Jardiance by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Sequel Med Tech, LLC | Unresolved — no canonical attribution shown | $149.69 | 19.6% | 1 | 2025 |
| Radius Health, Inc. | Unresolved — no canonical attribution shown | $143.68 | 18.8% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $124.74 | 16.3% | 1 | 2025 |
| Tandem Diabetes Care, Inc. | Unresolved — no canonical attribution shown | $116.14 | 15.2% | 2 | 2025 |
| CeQur Corporation | Unresolved — no canonical attribution shown | $114.20 | 14.9% | 1 | 2025 |
| Ascendis Pharma Endocrinology Inc | Unresolved — no canonical attribution shown | $96.43 | 12.6% | 1 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $18.85 | 2.5% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $744.88 | 7 |
| Education | $18.85 | 1 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| TWIIST Normalized: twiist |
Device | Sequel Med Tech, LLC | $149.69 | 1 | 2025 |
Source payment records
|
|||||
| Tymlos Normalized: tymlos |
Drug | Radius Health, Inc. | $143.68 | 1 | 2025 |
Source payment records
|
|||||
| t:slim X2 Insulin Pump with Control-IQ Normalized: t slim x2 insulin pump with control iq |
Device | Tandem Diabetes Care, Inc. | $116.14 | 2 | 2025 |
Source payment records
|
|||||
| CeQur Simplicity Normalized: cequr simplicity |
Device | CeQur Corporation | $114.20 | 1 | 2025 |
Source payment records
|
|||||
| Yorvipath Normalized: yorvipath |
Drug | Ascendis Pharma Endocrinology Inc | $96.43 | 1 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $18.85 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 229 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Amgen Inc. Exact reporting entity; no affiliate inference |
2025 | PROLIA open payments reported associated product |
CMS Open Payments — General Payments 20867 supporting records · 11744 recipient NPIs · example record 1226874448 |
Prolia · 2024 Exact normalized brand match · 1 Part D row |
34 | 18 |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
229 | 62 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Trulicity | Dulaglutide | 390 | 84 |
| Atorvastatin Calcium | Atorvastatin Calcium | 374 | 99 |
| Levothyroxine Sodium | Levothyroxine Sodium | 368 | 101 |
| Metformin Hcl Er | Metformin Hcl | 336 | 101 |
| Jardiance | Empagliflozin | 229 | 62 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 187 | 61 |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 168 | 69 |
| Ozempic | Semaglutide | 161 | 40 |
| Glipizide Er | Glipizide | 150 | 45 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 149 | 42 |
| Metformin Hcl | Metformin Hcl | 144 | 40 |
| Methimazole | Methimazole | 105 | 30 |
| Lisinopril | Lisinopril | 101 | 24 |
| Alendronate Sodium | Alendronate Sodium | 86 | 30 |
| Tresiba Flextouch U-100 | Insulin Degludec | 81 | 29 |
| Humalog Kwikpen U-100 | Insulin Lispro | 80 | 31 |
| Synthroid | Levothyroxine Sodium | 76 | 19 |
| Novolog Flexpen | Insulin Aspart | 75 | 33 |
| Mounjaro | Tirzepatide | 74 | 13 |
| Losartan Potassium | Losartan Potassium | 63 | 22 |
| Unithroid | Levothyroxine Sodium | 59 | 17 |
| Amlodipine Besylate | Amlodipine Besylate | 57 | 19 |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 51 | 16 |
| Januvia | Sitagliptin Phosphate | 50 | 12 |
| Ezetimibe | Ezetimibe | 48 | 17 |
| Farxiga | Dapagliflozin Propanediol | 47 | 12 |
| Droplet Pen Needle | Pen Needle, Diabetic | 42 | 15 |
| Tresiba Flextouch U-200 | Insulin Degludec | 39 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 38 | 14 |
| Prolia | Denosumab | 34 | 18 |
| Fiasp Flextouch | Insulin Aspart (Niacinamide) | 30 | suppressed |
| Humalog | Insulin Lispro | 30 | suppressed |
| Glimepiride | Glimepiride | 26 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 26 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 25 | suppressed |
| Testosterone | Testosterone | 24 | suppressed |
| Hydrocortisone | Hydrocortisone | 22 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 20 | suppressed |
| Lyumjev Kwikpen U-100 | Insulin Lispro-Aabc | 19 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 19 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 18 | suppressed |
| Simvastatin | Simvastatin | 17 | suppressed |
| Cabergoline | Cabergoline | 13 | suppressed |
| Dropsafe Prep Pads | Alcohol Antiseptic Pads | 12 | suppressed |
| Humulin N | Insulin Nph Human Isophane | 12 | suppressed |
| Hydrochlorothiazide | Hydrochlorothiazide | 12 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 12 | suppressed |
| Ultra-Fine Micro Pen Needle | Pen Needle, Diabetic | 12 | suppressed |
| Gabapentin | Gabapentin | 11 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 11 | suppressed |
| Ramipril | Ramipril | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $763.73 · 8 records | Sequel Med Tech, LLC | CeQur Simplicity, JARDIANCE, TWIIST, Tymlos, Yorvipath, t:slim X2 Insulin Pump with Control-IQ | 2 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Jardiance play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Amgen Inc.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error